BACKGROUND: Osteopetrosis, a genetic disease characterised by osteoclast failure, is classified into three forms: infantile malignant autosomal recessive osteopetrosis (ARO), intermediate autosomal recessive osteopetrosis (IRO), and autosomal dominant osteopetrosis (ADO). METHODS: We studied 49 patients, 21 with ARO, one with IRO, and 27 with type II ADO (ADO II). RESULTS: Most ARO patients bore known or novel (one case) ATP6i (TCIRG1) gene mutations. Six ADO II patients had no mutations in ClCN7, the only so far recognised gene implicated, suggesting involvement of yet unknown genes. Identical ClCN7 mutations produced differing phenotypes with variable degrees of severity. In ADO II, serum tartrate resistant acid phosphatase was always elevated. Bone alkaline phosphatase (BALP) was generally low, but osteocalcin was high, suggesting perturbed osteoblast differentiation or function. In contrast, BALP was high in ARO patients. Elevated osteoclast surface/bone surface was noted in biopsies from most ARO patients. Cases with high osteoclasts also showed increased osteoblast surface/bone surface. ARO osteoclasts were morphologically normal, with unaltered formation rates, intracellular pH handling, and response to acidification. Their resorption activity was greatly reduced, but not abolished. In control osteoclasts, all resorption activity was abolished by combined inhibition of proton pumping and sodium/proton antiport. CONCLUSIONS: These findings provide a rationale for novel therapies targeting pH handling mechanisms in osteoclasts and their microenvironment.
BACKGROUND: Osteopetrosis, a genetic disease characterised by osteoclast failure, is classified into three forms: infantile malignant autosomal recessive osteopetrosis (ARO), intermediate autosomal recessive osteopetrosis (IRO), and autosomal dominant osteopetrosis (ADO). METHODS: We studied 49 patients, 21 with ARO, one with IRO, and 27 with type II ADO (ADO II). RESULTS: Most ARO patients bore known or novel (one case) ATP6i (TCIRG1) gene mutations. Six ADO II patients had no mutations in ClCN7, the only so far recognised gene implicated, suggesting involvement of yet unknown genes. Identical ClCN7 mutations produced differing phenotypes with variable degrees of severity. In ADO II, serum tartrate resistant acid phosphatase was always elevated. Bone alkaline phosphatase (BALP) was generally low, but osteocalcin was high, suggesting perturbed osteoblast differentiation or function. In contrast, BALP was high in ARO patients. Elevated osteoclast surface/bone surface was noted in biopsies from most ARO patients. Cases with high osteoclasts also showed increased osteoblast surface/bone surface. ARO osteoclasts were morphologically normal, with unaltered formation rates, intracellular pH handling, and response to acidification. Their resorption activity was greatly reduced, but not abolished. In control osteoclasts, all resorption activity was abolished by combined inhibition of proton pumping and sodium/proton antiport. CONCLUSIONS: These findings provide a rationale for novel therapies targeting pH handling mechanisms in osteoclasts and their microenvironment.
Authors: U Kornak; D Kasper; M R Bösl; E Kaiser; M Schweizer; A Schulz; W Friedrich; G Delling; T J Jentsch Journal: Cell Date: 2001-01-26 Impact factor: 41.582
Authors: E Cleiren; O Bénichou; E Van Hul; J Gram; J Bollerslev; F R Singer; K Beaverson; A Aledo; M P Whyte; T Yoneyama; M C deVernejoul; W Van Hul Journal: Hum Mol Genet Date: 2001-12-01 Impact factor: 6.150
Authors: U Kornak; A Schulz; W Friedrich; S Uhlhaas; B Kremens; T Voit; C Hasan; U Bode; T J Jentsch; C Kubisch Journal: Hum Mol Genet Date: 2000-08-12 Impact factor: 6.150
Authors: A Teti; S Migliaccio; A Taranta; S Bernardini; G De Rossi; M Luciani; M Iacobini; L De Felice; R Boldrini; C Bosman; A Corsi; P Bianco Journal: J Bone Miner Res Date: 1999-12 Impact factor: 6.741
Authors: A Frattini; P J Orchard; C Sobacchi; S Giliani; M Abinun; J P Mattsson; D J Keeling; A K Andersson; P Wallbrandt; L Zecca; L D Notarangelo; P Vezzoni; A Villa Journal: Nat Genet Date: 2000-07 Impact factor: 38.330
Authors: Anna Taranta; Silvia Migliaccio; Irene Recchia; Maurizio Caniglia; Matteo Luciani; Giulio De Rossi; Carlo Dionisi-Vici; Rita M Pinto; Paola Francalanci; Renata Boldrini; Edoardo Lanino; Giorgio Dini; Giuseppe Morreale; Stuart H Ralston; Anna Villa; Paolo Vezzoni; Domenico Del Principe; Flaminia Cassiani; Giuseppe Palumbo; Anna Teti Journal: Am J Pathol Date: 2003-01 Impact factor: 4.307
Authors: Larry Pederson; Ming Ruan; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler Journal: Proc Natl Acad Sci U S A Date: 2008-12-15 Impact factor: 11.205
Authors: Thorsten Schinke; Arndt F Schilling; Anke Baranowsky; Sebastian Seitz; Robert P Marshall; Tilman Linn; Michael Blaeker; Antje K Huebner; Ansgar Schulz; Ronald Simon; Matthias Gebauer; Matthias Priemel; Uwe Kornak; Sandra Perkovic; Florian Barvencik; F Timo Beil; Andrea Del Fattore; Annalisa Frattini; Thomas Streichert; Klaus Pueschel; Anna Villa; Klaus-Michael Debatin; Johannes M Rueger; Anna Teti; Jozef Zustin; Guido Sauter; Michael Amling Journal: Nat Med Date: 2009-06 Impact factor: 53.440
Authors: T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen Journal: Hum Genet Date: 2008-11-06 Impact factor: 4.132